JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy

Jak inhibitors are potent anti-inflammatory drugs that have the potential to dampen the hyperactive inflammatory response associated with severe COVID-19. We reviewed the clinical outcomes of 218 patients with COVID-19 hospitalized for severe pneumonia and treated with ruxolitinib through a compassi...

Descripción completa

Detalles Bibliográficos
Autores principales: Vannucchi, Alessandro Maria, Mortara, Andrea, D’Alessio, Andrea, Morelli, Mara, Tedeschi, Alberto, Festuccia, Moreno Benedetto, Monforte, Antonella D’Arminio, Capochiani, Enrico, Selleri, Carmine, Simonetti, Federico, Saracino, Annalisa, Rapezzi, Davide, Badagliacca, Maria Rita, Falasca, Katia, Molteni, Alfredo, Palazzolo, Roberto, Schettino, Giuliano, Bocchia, Monica, Turrini, Mauro, Ascierto, Paolo A., Zuurman, Mike, Paley, Carole, Coco, Paola, Saglio, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397012/
https://www.ncbi.nlm.nih.gov/pubmed/34442045
http://dx.doi.org/10.3390/jcm10163752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397012/
https://www.ncbi.nlm.nih.gov/pubmed/34442045
http://dx.doi.org/10.3390/jcm10163752

Ejemplares similares